ClinicalTrials.gg
CompletedNCT01520818Updated Jan 4, 2017

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

A Phase 3 interventional study of biphasic insulin aspart 50 and biphasic insulin aspart 70 in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 77 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-04.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 142 studies testing Insulin Aspart in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. Insulin Aspart · Diabetes Mellitus.

Enrollment
6th of 142
666 · median 80
Started
2000
with 3 others
Phase 3
51 of 142
1 open now
Registered
82nd of 142
by date
Lead sponsor
123 of 142
Novo Nordisk A/S

Among the 142 studies testing Insulin Aspart in Diabetes Mellitus, this one is the 6th largest by enrollment, is one of 4 that started in 2000, is one of 51 in phase 3, and was the 82nd registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 142 studies testing Insulin Aspart in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing Insulin Aspart in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or Type 2 diabetes
  • Current treatment with BHI 30 twice daily as the only insulin therapy for at least 3 months, with or without combination with oral hypoglycaemic agents
  • (BMI) maximum 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol dependence
  • Impaired hepatic function
  • Impaired renal function
  • Cardiac disease
  • Proliferative retinopathy
  • Total daily insulin dose at least 1.80 IU/kg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
666 participants (actual)

Study arms

  • Experimental
    BIAsp 50 or 70

    Drug: biphasic insulin aspart 50 · Drug: biphasic insulin aspart 70

  • Active comparator
    BHI 30

    Drug: biphasic human insulin 30

Interventions

  • DrugInsulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50

  • DrugInsulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70

  • Administered subcutaneously (s.c., under the skin), twice a day

06

What researchers measure

Primary outcomes

  1. HbA1c (glycosylated haemoglobin A1c)

Secondary outcomes

  1. Blood glucose profiles

  2. Adverse events

  3. Hypoglycaemic episodes

  4. Quality of Life (QoL) assessed via World Health Organization Diabetes Treatment Satisfaction Questionnaire (WHO DTSQ)

  5. Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2)

07

Study locations

77 sites
  • Novo Nordisk Investigational Site
    Aalst, 9300, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1020, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Genk, 3600, Belgium
  • Novo Nordisk Investigational Site
    Jumet, 6040, Belgium
  • Novo Nordisk Investigational Site
    Liège, 4000, Belgium
  • Novo Nordisk Investigational Site
    Amiens, France
  • Novo Nordisk Investigational Site
    Avignon, 84902, France
  • Novo Nordisk Investigational Site
    Bagnols-sur-ceze, 30200, France
  • Novo Nordisk Investigational Site
    Bordeaux, 33076, France
  • Novo Nordisk Investigational Site
    Caen, 14033, France
  • Novo Nordisk Investigational Site
    Colmar, 68024, France
  • Novo Nordisk Investigational Site
    DIJON cedex, 21079, France
  • Novo Nordisk Investigational Site
    Dommartin Les Toul, 54201, France
  • Novo Nordisk Investigational Site
    GRENOBLE cedex, 38043, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    Lorient, 56322, France
  • Novo Nordisk Investigational Site
    Lyon, 69437, France
  • Novo Nordisk Investigational Site
    Macon, 71000, France
  • Novo Nordisk Investigational Site
    Marseille, 13009, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    NEVERS cedex, 58033, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Orleans, France
  • Novo Nordisk Investigational Site
    Paris, 75007, France
  • Novo Nordisk Investigational Site
    Paris, 75014, France
  • Novo Nordisk Investigational Site
    Reims, 51056, France
  • Novo Nordisk Investigational Site
    Roubaix, 59056, France
  • Novo Nordisk Investigational Site
    Saint Etienne, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67091, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 15, Ireland
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 7, Ireland
  • Novo Nordisk Investigational Site
    Dublin, Ireland
  • Novo Nordisk Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • Novo Nordisk Investigational Site
    Amersfoort, 3816 CP, Netherlands
  • Novo Nordisk Investigational Site
    Arnhem, Netherlands
  • Novo Nordisk Investigational Site
    Beverwijk, Netherlands
  • Novo Nordisk Investigational Site
    Delft, 2625 AD, Netherlands
  • Novo Nordisk Investigational Site
    Den Bosch, 5223 GV, Netherlands
  • Novo Nordisk Investigational Site
    Den Haag, 2597 AX, Netherlands
  • Novo Nordisk Investigational Site
    Einhoven, Netherlands
  • Novo Nordisk Investigational Site
    Hengelo, 7555 DL, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3011 TD, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3021 HC, Netherlands
  • Novo Nordisk Investigational Site
    Ayrsh, KA2 0BE, United Kingdom
  • Novo Nordisk Investigational Site
    Ayr, KA6 6DX, United Kingdom
  • Novo Nordisk Investigational Site
    Bath, BA1 3NG, United Kingdom
  • Novo Nordisk Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • Novo Nordisk Investigational Site
    Brighton, BN2 5BE, United Kingdom
  • Novo Nordisk Investigational Site
    Coventry, CV1 4FH, United Kingdom
  • Novo Nordisk Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Novo Nordisk Investigational Site
    Edgware, HA8 0AD, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novo Nordisk Investigational Site
    Exeter, EX2 5AX, United Kingdom
  • Novo Nordisk Investigational Site
    Glasgow, G51 4TF, United Kingdom
  • Novo Nordisk Investigational Site
    Haywards Heath, RH16 4EX, United Kingdom
  • Novo Nordisk Investigational Site
    Ipswich, IP4 5PD, United Kingdom
  • Novo Nordisk Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • Novo Nordisk Investigational Site
    London, E11 1NR, United Kingdom
  • Novo Nordisk Investigational Site
    London, N19 3UA, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 0JE, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M8 5RB, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Paisley, PA2 9PL, United Kingdom
  • Novo Nordisk Investigational Site
    Poole, BH15 2JB, United Kingdom
  • Novo Nordisk Investigational Site
    Rugby, CV22 5PX, United Kingdom
  • Novo Nordisk Investigational Site
    Scunthorpe, DN15 7BH, United Kingdom
  • Novo Nordisk Investigational Site
    Southampton, SO14 OYG, United Kingdom
  • Novo Nordisk Investigational Site
    Sunderland, SR4 7TP, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
  • Novo Nordisk Investigational Site
    Watford, WD18 0HB, United Kingdom
  • Novo Nordisk Investigational Site
    Whiston, L35 5DR, United Kingdom
08

References and documents

Publications

  • Clements MR, Tits J, Kinsley BT, Rastam J, Friberg HH, Ligthelm RJ. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab. 2008 Mar;10(3):229-37. doi: 10.1111/j.1463-1326.2006.00687.x. PubMed 18269638 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2000, a primary completion of Apr 2001 and a completion of Apr 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2012
First posted
Jan 30, 2012
Start
Mar 2000
Primary completionActual
Apr 2001
CompletionActual
Apr 2001
Last update
Jan 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01520818
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 30, 2012
Start date
Mar 2000
Primary completion
Apr 2001
Completion
Apr 2001
Last update
Jan 4, 2017

Study contacts

Global Clinical Registry (GCR,1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion